radiotherapy market in 2018. The growing incidence of prostate cancer and the high success
rates and minimal long-term risks achieved with external beam radiotherapy are the major
factors driving the growth of this market segment.
Particle beam therapy to register the highest CAGR in the external beam radiotherapy market
during the forecast period
Based on type, the external beam radiotherapy market is classified into IGRT, IMRT, stereotactic
therapy, particle beam therapy, and 3D-CRT. The IMRT segment is further classified into VMAT
and TomoTherapy. The particle beam therapy segment is expected to witness the highest CAGR
during the forecast period. Advancements in the field of particle beam therapy (such as PBS)
and increasing research activities in the field of radiation oncology using proton therapy
systems are the key factors driving the growth of this segment.
North America to dominate the radiotherapy market during the forecast period
The radiotherapy market is segmented into four regional segments, namely, North America,
Europe, Asia Pacific, and the Rest of the World. The North American region is expected to
account for the largest share of the radiotherapy market in 2018. The rising incidence of cancer,
easy accessibility and high adoption of advanced diagnostic technologies (owing to the
significant per capita annual healthcare expenditure in the US and Canada), and favorable
government initiatives that are creating awareness and promoting the adoption of radiotherapy
among key end users are some of the major factors driving the growth of the radiotherapy
market in North America.
The major players operating in the radiotherapy market are Varian Medical Systems, Inc. (US),
Elekta (Sweden), Accuray Incorporated (US), Ion Beam Applications SA (Belgium), ViewRay, Inc.
(US), IsoRay Medical, Inc. (US), Hitachi Ltd. (Japan), Panacea Medical Technologies Pvt. Ltd.
(India), Provision Healthcare (US), Mevion Medical Systems, Inc. (US), Sumitomo Heavy
Industries, Ltd. (Japan), Optivus Proton Therapy, Inc. (US), P-cure Ltd. (Israel), Theragenics
Corporation (US), and C.R.Bard, Inc. (US).